Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | IARS1 | P41252 | 1/20 | 0.32 |
| ▸ | PDE8A | O60658 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008382 | 0.86 | ADORA2A (0.32) | PDE2APDE4DPOLBCDK1 | |
| SCHEMBL20008037 | 0.73 | ATG7 (0.40) | CA1CA2CA9CDK1 | |
| SCHEMBL20008103 | 0.72 | ATG7 (0.34) | POLBCDK1 | |
| SCHEMBL20008410 | 0.72 | ATG7 (0.36) | — | |
| SCHEMBL20008098 | 0.71 | CDK1 (0.41) | CA1CA2CA9CDK1 | |
| SCHEMBL20007970 | 0.71 | DNPH1 (0.38) | CDK1 | |
| SCHEMBL23080208 | 0.71 | ADK (0.32) | — | |
| SCHEMBL1799584 | 0.70 | CA1 (0.73) | CA1CA2CA4CA9IARS1 | |
| SCHEMBL20008212 | 0.70 | ADORA3 (0.34) | — | |
| SCHEMBL23080276 | 0.69 | ATG7 (0.34) | PDE2APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | CA1 3790/4885CA2 4021/4885CA4 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.